Company Overview and News
Skechers U.S.A., Inc. (SKX - Free Report) is slated to release first-quarter 2018 results on Apr 19 after the market closes. In the trailing four quarters, it had outperformed the Zacks Consensus Estimate by an average of 23.6%. In the preceding two quarters, it surpassed the consensus mark by 61.5% and 37.2%, respectively.
Bargain hunters are back on the streets buying furniture and appliances, and dining out, as U.S. retail sales rebounded sharply in the month of March, thus ending the streak of three straight declines. With strengthening labor market, tax reform and rising incomes Americans look much more confident now. Moreover, annual tax refunds are also likely to increase their propensity to consume. Clearly, consumer spending — one of the pivotal factors driving the economy — is likely to remain strong in the months ahead.
It is unlikely to escape the roller-coaster ride that the U.S. market has undergone lately, thanks to the concerns regarding a trade-war with China, the outcomes of the recent attack on Syria and anticipation of rate hikes by the Fed. During this time, we find The Gap Inc. (GPS - Free Report) as a stock that has shown relative stability and is a safe haven supported by its long-term earnings growth rate of 8%.
Bed Bath & Beyond Inc. (BBBY - Free Report) is among the stocks that delivered solid top- and bottom-line performances in the near past. Notably, the company reported the second straight quarter of earnings and sales beat in fourth-quarter fiscal 2017. Results were driven by solid sales growth, owing to the progress on its transformation efforts and other customer-centric initiatives. (Read More: Bed Bath & Beyond Down Despite Earnings Beat in Q4).
The Wall Street is juggling with various macro and micro issues at the moment, including U.S.-China trade dispute, Facebook data breach, apprehensions about three or more rate hikes by the Fed this year and latest being the airstrike on Syria. All these events have kept the market on tenterhooks with investors scurrying for safe havens. A clear reflection of these factors were visible in the recent outcome of the Consumer Sentiment data that declined from its 14-year high.
Simon's debt ratings are among the best unsecured debt ratings in the REIT industry, and this underscores the balance sheet strength.
Carter's doubled its revenue within 7 years, and the company still has many growth opportunities to expand the business.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Rite Aid Corporation (RAD - Free Report) delivered better-than-expected bottom-line results for fourth-quarter fiscal 2018, marking a considerable improvement from its recent trend. However, the top line continued to disappoint, lagging the estimates and declining year over year. The company’s improved bottom-line results can be attributed to the stabilization of reimbursement rates, a decline in drug purchasing costs and a record number of immunizations that enhanced pharmacy margins for the quarter.
Zumiez Inc. has been riding high on a favorable comparable-store sales (comps) trend. The company continued this trend by reporting robust sales and comps numbers for March as well, marking the 13th straight month of comps growth. Consequently, shares of the company were up nearly 2% in after-hours trading on Apr 11. This mall-based specialty retailer recorded 12.6% comps growth for the five-week period ended Apr 7, 2018, compared with 1.
Fast Retailing Co. on Thursday raised its full-year profit forecast by 13 percent on the back of robust growth across Asia, as the owner of clothing chain Uniqlo continues to chase the top spot in global apparel sales.
Investors who want to understand why the market's top technology stocks are so misunderstood need only to watch Facebook CEO Mark Zuckerberg's testimony before Congress, CNBC's Jim Cramer said on Wednesday.
As retailers turn their focus to reaching consumers in the most effective ways possible, big data is becoming a key tool for companies like The Gap, Inc., President and CEO Art Peck told CNBC.
Fastenal Company (FAST - Free Report) delivered strong results in the first quarter of 2018 owing to higher market demand, growth in industrial vending business and existing Onsite locations. Sales through vending devices consistently grew at a strong double-digit pace in the quarter, due to the increase in the installed base and higher revenue per device. Earnings & Sales Detail Fastenal’s adjusted earnings of 61 cents per share in the first quarter of 2018 were in line with the Zacks Consensus Estimate.
Taking a break from the hot U.S.-China friction headlines, here we bring for you an interesting observation on how apparel retailing has been adapting well to e-commerce and omni-channel techniques. Looking almost a year back and before, the apparel retail segment witnessed a setback due to the evolving trends in the retail industry as smart phones started becoming the primary avenue to make purchases.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET